Curis INC 10-Q quarterly reports

Curis, Inc. files its Q1 2026 10-Q, detailing ongoing development of emavusertib, significant net loss, and substantial doubt about its ability to continue as a going concern.

Curis, Inc. reported a net loss of $26.9 million for the nine months ended September 30, 2025, and disclosed substantial doubt about its ability to continue as a going concern, leading to the sale of its Erivedge royalty interest post-period end.

Curis, Inc. reports continued losses and significant doubt about its ability to continue as a going concern, despite progress in its emavusertib clinical programs.

Curis Inc. reports a net loss for Q1 2025 and acknowledges substantial doubt about its ability to continue as a going concern.

Curis Inc. reported its third quarter 2024 financial results, highlighting ongoing research and development efforts for emavusertib while also acknowledging substantial doubt about the company's ability to continue as a going concern.

Curis Inc. reported its financial results for the second quarter of 2024, highlighting ongoing clinical trials for emavusertib and a strategic shift to focus on key programs.

Curis Inc. reported a net loss of $11.9 million for the first quarter of 2024 and faces substantial doubt about its ability to continue as a going concern.